Navigation Links
Pure MHC and Catalent Sign RL21 Anti-Cancer Development Deal
Date:11/21/2013

Somerset, NJ, and Austin, TX (PRWEB) November 21, 2013

Pure MHC, LLC, a provider of MHC-based diagnostics and therapeutics, and Catalent Pharma Solutions, the global leader in drug development solutions and advanced delivery technologies for pharmaceutical, biologic and consumer health products, today announced the signing of a product development agreement. Under the terms of the agreement, Catalent will develop a humanized version of Pure MHC’s proprietary RL21A antibody and engineer a cell line to express the antibody using Catalent’s GPEx® technology. Catalent will subsequently produce purified monoclonal antibodies to support Pure MHC’s preclinical development in preparation for clinical trials with humanized RL21A for the treatment of cancer. GPEx technology is used to generate mammalian cells with high yields and stability, helping to speed drugs to clinic.

“We are confident that our partnership with Catalent will result in the development of the enhanced antibodies necessary to help get RL21A into the clinic more quickly,” said Thomas Harlan, CEO of Pure MHC, “Our ultimate goal for this technology is to one day provide cancer patients with a treatment option that is safer and more effective than those available today.”

“We are delighted to again demonstrate how GPEx technology, together with Catalent’s development and manufacturing expertise, can support development of novel therapies and enable companies such as Pure MHC to validate their unique target screening methodology,” said Jonathan Arnold, VP, General Manager of Catalent’s Advanced Delivery Technologies business.

Pure MHC has developed a suite of MHC/ligand targets that recognize cancerous cells in addition to producing monoclonal antibodies for these distinct MHC/ligand cancer targets. Antibodies such as RL21A distinguish primary cancers from healthy tissue and, in animal models, have been shown to arrest tumor development.

About Catalent
Catalent Pharma Solutions is the global leader in development solutions and advanced drug delivery technologies, providing worldwide clinical and commercial supply capabilities for drugs, biologics and consumer health products. With over 75 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable product supply. Catalent employs approximately 8,500 people, including over 1,000 scientists, at nearly 30 facilities across 5 continents and generates more than $1.7 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit http://www.catalent.com.

More products. Better treatments. Reliably supplied.™

About Pure MHC
Pure MHC is an immunology company focused on MHC-based diagnostics and therapeutics that was formed from innovative technologies developed in two Emergent Technologies portfolio companies, Pure Protein, LLC and Receptor Logic, LLC, to provide a novel solution for the treatment of infectious diseases and cancers. Pure Protein, founded in 1999 and led by William Hildebrand, PhD, has technology to manufacture soluble HLA proteins that are used in a proprietary method of novel immunogenic epitope discovery and validation. Receptor Logic, founded in 2003 and led by Jon Weidanz, PhD, has proprietary technology for generating T-cell Receptor mimics from novel epitopes defined by Pure Protein. For more information, visit http://www.puremhc.com.

Read the full story at http://www.prweb.com/releases/2013/11/prweb11352881.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Catalent Creates New Advanced Delivery Technologies Business Unit
2. Catalent’s Clinical Trial Supply Facility in Shanghai, China Opens for Business
3. Moffitt Cancer Center researchers develop and test new anti-cancer vaccine
4. 1960s-era anti-cancer drug points to treatments for Lou Gehrigs disease
5. Specialized MRI scans assess value of anti-cancer chemotherapy long before tumors shown to shrink
6. First trial in humans of minicells: A completely new way of delivering anti-cancer drugs
7. Development of the first way to make large amounts of promising anti-cancer substance
8. Progress after recent breakthrough which opened new chapter in anti-cancer cell therapies
9. Overcoming resistance to anti-cancer drugs by targeting cell powerhouses
10. Anti-cancer drug viewed as possible Alzheimers treatment doesnt work in UF study
11. New understanding of why anti-cancer therapy stops working at a specific stage
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2020)... ... , ... Medisend College of Biomedical Engineering Technology, a Dallas-based ... prepares graduates for professional careers as field service engineers and biomedical equipment technicians, ... Ms. Williams currently serves as Associate Vice Chancellor of Workforce and Community Initiatives ...
(Date:6/28/2020)... MONTREAL (PRWEB) , ... June 27, 2020 , ... The ... cashmere folds of hundreds of rolls of toilet paper. Yet, it was the first ... hoarding seems sensible in theory. The more you have stockpiled, the less need to ...
(Date:6/25/2020)... ... 25, 2020 , ... Denials Management, Inc. has just published The Health Insurance ... appeals for denials of mental health and substance use disorder (MH/SUD) treatment services. It ... rights and explain the steps in the appeals process. Complimentary copies of the ...
(Date:6/24/2020)... Ga. (PRWEB) , ... June 24, 2020 , ... ... and population health management, today announced that Wexford Physician Hospital Organization (PHO) has ... quality and cost goals within the framework of value-based care. Use of Population ...
(Date:6/23/2020)... ... ... Oak Street Health, a network of primary care centers that delivers value-based care ... the company’s first centers in New York and Mississippi anticipated to open later this ... center in Jackson, Miss. , “The planned opening of our first centers in ...
Breaking Medicine News(10 mins):
(Date:6/23/2020)... ... June 23, 2020 , ... ... leading provider of center-based, Applied Behavioral Analysis ("ABA") therapy, today announced the ... in the greater-Indianapolis market. This acquisition will make Lighthouse Autism Center one ...
(Date:6/23/2020)... ... June 23, 2020 , ... Construction at the Kasemrad Hospital ... a greatly enlarged and enhanced medical facility. Penetron crystalline technology was ... rooftop garden. , Part of the Bangkok Chain Hospital (BCH) network of private ...
(Date:6/19/2020)... ... June 19, 2020 , ... Food Equality Initiative (FEI), a nonprofit ... allergies and celiac disease announced the first of the “ For the Health” webinar ... for Friday, June 19, 2020, from 11:00, am EST - 12:00 pm EST. ...
Breaking Medicine Technology: